LH — Labcorp Holdings Inc.

Summary of Labcorp Holdings Q2 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $3.7 billion, up 6% year-over-year.
• Adjusted Earnings Per Share (EPS): $4.99, a 15% increase from the previous year.
• Free Cash Flow: $314 million, down from $543 million year-over-year, primarily due to working capital timing and increased capital expenditures.
• Adjusted Operating Margin: Improved by 70 basis points to 15.8%.
• Diagnostics Revenue: $2.9 billion, a 5.5% increase; organic growth at 3.6%.
• Biopharma Laboratory Services (BLS) Revenue: $836 million, up 6.5%; organic constant currency growth at 6.2%.

2. Strategic Updates and Business Highlights

• Continued expansion in specialty testing, particularly in oncology, neurology, autoimmune diseases, and women's health, with double-digit revenue growth in these areas.
• Launched ColoSense, an FDA-approved at-home colorectal cancer screening test, enhancing patient access.
• Strengthened partnerships with health systems and biopharmaceutical clients, including acquisitions of outreach laboratory services and Tribal Diagnostics.
• Consumer health business showed strong double-digit growth, driven by Labcorp OnDemand offerings, including the new Marker by Labcorp Genetic Health Panel.
• Enhanced technological capabilities through collaborations, such as with Epic, to improve access to Labcorp's diagnostic tests.

3. Forward Guidance and Outlook

• Full-Year Revenue Guidance: Raised midpoint; expected growth of 5.4% to 6.3%.
• Diagnostics Segment Revenue Guidance: Expected growth of 5.3% to 6%.
• BLS Segment Revenue Guidance: Expected growth of 5.5% to 6.5%, with improved outlook for Early Development.
• Adjusted EPS Guidance: Increased to a range of $18.10 to $18.55, implying growth of over 11% at the midpoint.
• Free Cash Flow Guidance: Expected to remain between $1.24 billion to $1.36 billion.

4. Bad News, Challenges, or Points of Concern

• Bad Debt and ACA Impact: Although bad debt remains consistent, there are concerns regarding potential headwinds from ACA changes, which could impact volume by approximately 30 basis points.
• Free Cash Flow Decline: Notable decrease in free cash flow compared to the previous year, attributed to working capital timing and increased capital expenditures.
• Competitive Pressures: Some analysts noted that Labcorp's organic growth was lower compared to peers, raising questions about competitive positioning and market share.

5. Notable Q&A Insights

• Utilization and Volume Growth: Management emphasized strong organic growth in diagnostics, particularly in specialty testing, which tends to have higher test volumes per patient.
• Market Positioning: Labcorp is focusing on higher-margin segments and avoiding lower-margin partnerships, which may impact overall growth metrics.
• Consumer Strategy: Labcorp OnDemand is a key growth area, with a focus on maintaining profitability amidst a competitive landscape in direct-to-consumer testing.
• PAMA and M&A Outlook: Management remains optimistic about M&A opportunities, particularly with hospitals under pressure, while also preparing for potential impacts from PAMA regulations.

Overall, Labcorp demonstrated solid financial performance in Q2 2026, with strategic initiatives aimed at enhancing growth and profitability, despite facing some market challenges and competitive pressures.